Skip to main content
Skip to main content
Back to Grand Rounds
Grand RoundsWeekly Evidence Brief

Cardiothoracic Surgery

Edition

30-Second Takeaway

  • POAF after cardiac surgery is common, variably treated, and signals higher one-year AF recurrence and mortality.
  • Real-world TTVR delivers durable 30-day TR reduction with acceptable event rates and marked functional improvement.
  • CT size overestimates small NSCLC lesions near 20 mm, risking lobectomy overuse under size-only criteria.

Week ending April 18, 2026

Postoperative AF risk, emerging valve and pacing technologies, and nuanced lung cancer and ECMO management

POAF after cardiac surgery predicts one-year AF and mortality in a large prospective cohort

EUROPEAN HEART JOURNALApr 12, 2026

In this 12-country prospective cohort of 12,234 cardiac surgery patients, 31.8% developed new-onset POAF within 30 days. Discharge antithrombotic strategies varied substantially, with most patients receiving antiplatelet therapy and nearly half receiving amiodarone. At one year, clinical AF occurred in 6.9% with POAF versus 0.6% without (adjusted HR 11.30; 95% CI 8.17–15.70). POAF was also associated with higher all-cause mortality (3.0% vs 1.7%; adjusted HR 1.54; 95% CI 1.18–2.00).

Early US TTVR experience confirms high procedural success and rapid symptomatic improvement

JAMAApr 13, 2026

This STS/ACC TVT Registry analysis included 1034 attempted TTVR procedures for symptomatic severe TR at 82 US centers. Valve implantation succeeded in 98.4%, with mild or less TR in 98.4% post-procedure and 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%, stroke 0.2%, major bleeding 7.9%, and heart failure hospitalization 3.1%. New CIED implantation occurred in 15.9% of CIED-naive patients, indicating frequent pacing needs after TTVR. Functional status improved, with 82.7% in NYHA I/II and mean KCCQ-OS score improving by 22.4 points at 30 days.

CT–pathology discordance around 20 mm may drive lobectomy overuse in small NSCLC

CANCERSApr 14, 2026

This single-center series analyzed 1096 thoracoscopic clinical stage I NSCLC resections for CT–pathology tumor size agreement. CT overestimated small tumors (T1a: +4.21 mm) and underestimated larger lesions (≥T2: −7.49 mm) compared with pathology. Using CT >20 mm as a lobectomy trigger, 15.8% underwent lobectomy despite pathological size ≤20 mm, indicating potential overtreatment. Restricted cubic spline modeling with bootstrap-validated decision curve analysis suggested a 23 mm CT threshold as a better cutoff. A 23 mm threshold would have reclassified 108 patients to sublobar resection and reduced size-threshold-defined overtreatment by about half.

Mobile ICU-supported ECMO rapid response network improves efficiency and weaning

ISCIENCEApr 13, 2026

This retrospective cohort of 151 adults evaluated a mobile ICU-based ECMO rapid response team versus prior ad hoc ECMO care. The standardized regional workflow significantly shortened team response, priming, ECMO initiation, and inter-hospital transfer times. Mechanical complications decreased and weaning rates improved with the new model, without a statistically significant survival advantage. Findings support feasibility of a hub-and-spoke, mobile ICU ECMO network and justify prospective multicenter evaluation.

References

Numbered in order of appearance. Click any reference to view details.

Additional Reads

Optional additional studies from this edition.

Edition context

Clinical signal

  • Cardiac surgeons should treat POAF as a prognostic marker and standardize rhythm and antithrombotic strategies after surgery.
  • Heart teams can adopt TTVR for severe TR with expectations of rapid symptomatic gain and low early mortality and stroke.
  • Thoracic surgeons should avoid rigid CT size thresholds alone for resection extent decisions in small NSCLC.